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Introduction {#sec001}
============

The incidence of prostate cancer in Taiwan, although lower than that in Western countries, has been increasing. According to a Taiwanese annual cancer report in 2016, prostate cancer was the fifth most commonly diagnosed cancer in Taiwan, with a median age at diagnosis of 73 years old \[[@pone.0236026.ref001]\]. Thus, prostate cancer is becoming a serious health problem, especially in an ageing society. The established and definitive treatment for localised prostate cancer includes radical prostatectomy and radiotherapy; data on long-term outcomes of both treatments are available. However, many patients are concerned about periprocedural adverse events \[[@pone.0236026.ref002], [@pone.0236026.ref003]\], and aged patients, who tend to have comorbidities, have higher perioperative risk \[[@pone.0236026.ref004]\]; such patients may not tolerate major surgery and tend to be afraid of adverse events from radiotherapy.

Minimally invasive treatment modalities such as cryosurgical ablation of prostate and high-intensity focused ultrasound (HIFU) have been developed for patients with localised prostate cancer \[[@pone.0236026.ref005], [@pone.0236026.ref006]\]. HIFU uses a focused ultrasound wave that mechanically and thermally induces tissue damage, which causes coagulative necrosis through tissue cavitation and temperature elevation \[[@pone.0236026.ref007]\]. Long-term prospective comparative data on oncological outcomes after primary WG-HIFU are scarce \[[@pone.0236026.ref008]\]. Tsakiris et al. recommended HIFU, determining it to be oncologically safe for patients with stage T1c to T3 prostate cancer \[[@pone.0236026.ref009]\]. Data on outcomes of salvage treatment after primary HIFU for localised prostate cancer are also scarce. As HIFU devices evolve, the reported rate of adverse events has been reduced and is now at an acceptable level \[[@pone.0236026.ref006]\]. In this paper, we present our findings on the functional and medium-term oncological outcomes from our cohort study of men with localised prostate cancer who were treated with primary WG-HIFU. Outcomes of salvage treatment with radiotherapy and secondary HIFU are also presented.

Materials and methods {#sec002}
=====================

This retrospective single-institute study was approved by Kaohsiung Chang Gung Memorial Hospital Institutional Review Board (IRB number: 201101264B0). The IRB waived the requirement for informed consent. At our institution, 405 patients with prostate cancer have been treated with HIFU between December 2009 and July 2019. All patients were treated using Ablatherm^®^ Integrated Imaging (EDAP TMS SA, Vaulx-en-Velin, France) with transrectal ultrasonography guidance under general or spinal anaesthesia. From December 2009 to February 2015, 161 patients who were newly diagnosed with prostate cancer were enrolled. Of these patients, 13 patients received HIFU as salvage treatment for advanced prostate cancer. The remaining 148 patients underwent WG-HIFU for localised prostate cancer. Among these patients, 20 patients were excluded because their follow-up durations were less than 30 months. In total, 128 patients were included ([Fig 1](#pone.0236026.g001){ref-type="fig"}). All patients underwent either magnetic resonance imaging (MRI) or computed tomography of the pelvis, in addition to a bone scan for preoperative staging. Cancer staging was done according to the American Joint Committee on Cancer (7th edition) prostate cancer staging system. All patients underwent transurethral resection of the prostate 4 weeks before the HIFU procedure (if prostate volume was ≥40 ml) or simultaneously with the HIFU procedure (if prostate volume was \<40 ml). Risk of treatment failure was stratified according to D'Amico risk classification into low-, intermediate-, and high-risk groups. Our institutional protocol for follow-up after HIFU is based on the 3-monthly postoperative prostate-specific antigen (PSA) level. Biochemical recurrence, according to the Phoenix definition, is a post-HIFU PSA nadir +2 ng/ml. Post-HIFU prostate biopsy was not routinely arranged. It might be arranged because of biochemical recurrence. It might also be arranged for patients not meeting criteria of biochemical recurrence but worry about continuous elevation of PSA. If biochemical recurrence is detected, salvage treatment is arranged according to prostate biopsy results. In this study population, salvage therapies included secondary HIFU (34.2%) if residual cancer cells were present, in addition to radiation therapy (10.5%) or radiation therapy plus androgen deprivation therapy (ADT; 55.3%). Whether patients receive salvage treatment may be related to the results of prostate biopsy and patient's preference. Of patients with residual tumor noted, secondary HIFU will be arranged. Of patients with local lymph node metastasis suspected, salvage radiotherapy will be suggested. Salvage radiotherapy with half to one year of ADT is the standard strategy. Primary outcomes were biochemical recurrence--free survival (BRFS), salvage treatment--free survival, and metastasis-free survival.

![Outcome after salvage treatment.](pone.0236026.g001){#pone.0236026.g001}

The dose of salvage radiotherapy after HIFU is between 66 and 70 Gy, whereas the dose of primary radiotherapy is usually 74 Gy. The target of salvage radiotherapy includes the prostate and seminal vesicle, but may also include the pelvis lymph node, according to Roach's formula. The standard mode of delivery for primary HIFU is 100% acoustic power with a 6-s pulse of energy to create each discrete HIFU lesion, with a 4-s delay between each shot. The salvage mode of delivery for secondary HIFU is 90% acoustic power with a 4-s pulse and a 6-s waiting period.

The secondary outcomes were urinary incontinence (defined as one or more pads used daily for more than 3 months), *de novo* erectile dysfunction, acute epididymitis, bladder neck contracture, and urethral stricture (which required surgical treatment under anaesthesia). From March 2015, prophylactic bilateral vasectomy was performed immediately before HIFU and Bougienage at an outpatient clinic during follow-up to prevent postoperative epididymitis and urethral stricture, respectively.

MedCalc software (version 18.9.1) was used for all statistical analyses. Chi-square tests and two-sample *t* tests were used for intergroup comparisons, and the Kaplan--Meier test was used for time-to-event analysis. A *p* value \<0.05 was defined as statistically significant.

Results {#sec003}
=======

Baseline demographics {#sec004}
---------------------

This study included 128 patients. Patient characteristics are summarised in [Table 1](#pone.0236026.t001){ref-type="table"}. Mean age was 68.5 (range: 50.9--88.2). Mean prostate volume was 23.2 ml. According to D'Amico classification, the numbers of patients with low-, intermediate-, and high-risk disease were 14 (11.0%), 52 (40.6%), and 62 (48.4%). Median follow-up duration was 53.7 months (interquartile range \[IQR\]: 44.0--66.0).

10.1371/journal.pone.0236026.t001

###### Patient characteristics.

![](pone.0236026.t001){#pone.0236026.t001g}

  Characteristics                      
  ------------------------------------ -------------------
  Total number of men                  128
  Age (yr), mean (range)               68.5 (50.9--88.2)
  Prostate volume (ml), mean (range)   23.2 (6.7--71.1)
  Gleason score, N (%)                 
   \<7                                 35 (27.3%)
    = 7                                59 (46.1%)
   \>7                                 34 (26.6%)
  iPSA, N (%)                          
   \<10                                59 (46.1%)
   10--20                              43 (33.6%)
   \>20                                26 (20.3%)
  Stage                                
   \<T2b                               81 (63.3%)
   T2b                                 11 (8.6%)
   \>T2b                               36 (28.1%)
  D'Amico risk group, N (%)            
   Low                                 14 (11.0%)
   Intermediate                        52 (40.6%)
   High                                62 (48.4%)

Oncological outcomes {#sec005}
--------------------

Overall 5-year biochemical recurrence--free and salvage treatment--free survival rates after primary HIFU were 64.8% and 50.8%, respectively ([Table 2](#pone.0236026.t002){ref-type="table"}). The 5-year biochemical recurrence--free survival rates were 85.7%, 82.7%, and 45.2% for D'Amico low-, intermediate-, and high-risk groups, respectively ([Table 2](#pone.0236026.t002){ref-type="table"}). The 5-year salvage treatment--free survival rates were 71.4%, 69.2%, and 30.6% for D'Amico low-, intermediate-, and high-risk groups, respectively ([Table 2](#pone.0236026.t002){ref-type="table"}). Kaplan--Meier curves revealed significant differences in both biochemical recurrence--free and salvage treatment--free survival rate between different risk groups (Figs [2](#pone.0236026.g002){ref-type="fig"} and [3](#pone.0236026.g003){ref-type="fig"}). As shown in [Table 3](#pone.0236026.t003){ref-type="table"}, using Cox regression multivariate analysis, high-risk group is significantly associated with shorter biochemical recurrence free survival, salvage treatment free survival, and metastasis free survival. Median time to salvage treatment was 15.3 months after primary HIFU. Metastasis was detected in one patient in the intermediate-risk group and six patients in the high-risk group ([Fig 4](#pone.0236026.g004){ref-type="fig"}). Median nadir PSA was 0.10 ng/ml (IQR: 0.02--0.42 ng/ml). Median time to nadir PSA was 2.52 months (IQR: 1.10--3.87 months). We excluded 28 of 128 patients who were undergoing ADT during follow-up ([Fig 1](#pone.0236026.g001){ref-type="fig"}). Two patients were lost to follow-up within one year of HIFU. Of the remaining 98 patients, 60 (61.2%) patients had no biochemical recurrence and thus did not require any salvage treatment, and 38 (38.8%) patients received salvage treatment due to biochemical recurrence. The results of post-HIFU biopsy were shown as Tables [4](#pone.0236026.t004){ref-type="table"} and [5](#pone.0236026.t005){ref-type="table"}. In addition, the relationships between post-HIFU PSA and post-HIFU prostate biopsy were shown in [Table 6](#pone.0236026.t006){ref-type="table"}. There were 13, 21, and 4 patients receiving salvage HIFU, salvage radiation therapy with hormone therapy, and salvage radiation therapy without hormone therapy, respectively. Three out of four patients who received salvage radiation therapy were biochemical recurrence free. Fifteen out of 21 patients who received salvage radiation therapy with hormone therapy were biochemical recurrence free. In other words, in patients receiving salvage radiation therapy with or without hormone therapy, more than 70% of them became biochemical recurrence free. Thirteen patients underwent secondary HIFU. Seven patients were biochemical recurrence free. Among the six patients who had biochemical recurrence after secondary HIFU, four patients received salvage radiation therapy with hormone therapy as second-line salvage treatment, and all were biochemical recurrence free. In total, 38 (38.8%) of 98 patients received salvage treatment with radiotherapy or salvage HIFU. Twenty-nine patients (29/38, 76.3%) were biochemical recurrence free.

![Kaplan--Meier curves illustrating biochemical recurrence--free survival (Phoenix criteria), by D'Amico risk groups, in men undergoing WG-HIFU for prostate cancer.](pone.0236026.g002){#pone.0236026.g002}

![Kaplan--Meier curves illustrating salvage treatment--free survival, by D'Amico risk groups, in men undergoing WG-HIFU for prostate cancer.](pone.0236026.g003){#pone.0236026.g003}

![Kaplan--Meier curves illustrating metastasis-free survival, by D'Amico risk groups, in men undergoing WG-HIFU for prostate cancer.](pone.0236026.g004){#pone.0236026.g004}

10.1371/journal.pone.0236026.t002

###### Oncological outcomes.
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  Characteristics                                                      
  -------------------------------------------------------------------- ----------------------
  Follow-up period (mo), median (IQR)                                  53.73 (43.98--66.02)
  Nadir PSA (ng/ml), median (IQR)                                      0.10 (0.02--0.42)
  Time to PSA nadir (mo), median (IQR)                                 2.52 (1.10--3.87)
  Overall biochemical recurrence free survival at 5 yr                 64.8%
  Biochemical recurrence free survival at 5 yr by D'Amico risk group   
   Low                                                                 85.7%
   Intermediate                                                        82.7%
   High                                                                45.2%
  Overall salvage treatment-free survival at 5 yr                      50.8%
  Salvage treatment-free survival at 5 yr by D'Amico risk group        
   Low                                                                 71.4%
   Intermediate                                                        69.2%
   High                                                                30.6%
  Overall metastasis free survival at 5 yr                             94.5%

10.1371/journal.pone.0236026.t003

###### Cox regression multivariate analysis for oncologic outcome after primary WG-HIFU.
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  -------------------------------------- --------------------- ----------------------- ------------- ----------
  Biochemical recurrence free survival                                                               
  Characteristics                        Univariate analysis   Multivariate analysis                 
  HR (95% CI)                            *p* value             HR (95% CI)             *p* value     
  Age                                    0.95--1.02            0.36                                  
  Gleason score \<7                      ref.                                                        
  Gleason score = 7                      0.56--2.80            0.58                                  
  Gleason score \>7                      1.29--6.43            0.01                                  
  iPSA \<10                              ref.                                                        
  iPSA 10--20                            0.15--0.66            0.002                                 
  iPSA \>20                              0.14--0.84            0.02                                  
  Stage \<T2b                            ref.                                                        
  Stage = T2b                            0.66--5.71            0.22                                  
  Stage \>T2b                            1.67--5.70            0.0003                                
  low risk group                         ref.                                                        
  intermediate risk group                0.27--5.75            0.78                                  
  high risk group                        1.29--22.32           0.02                    2.28--8.90    \<0.0001
  Salvage treatment free survival                                                                    
  Characteristics                        Univariate analysis   Multivariate analysis                 
  HR (95% CI)                            *p* value             HR (95% CI)             *p* value     
  Age                                    0.96--1.03            0.75                                  
  Gleason score \<7                      ref.                                                        
  Gleason score = 7                      0.73--2.64            0.31                                  
  Gleason score \>7                      1.27--4.82            0.008                                 
  iPSA \<10                              ref.                                                        
  iPSA 10--20                            0.23--0.75            0.003                                 
  iPSA \>20                              0.25--0.95            0.03                                  
  Stage \<T2b                            ref.                                                        
  Stage = T2b                            0.37--2.96            0.93                                  
  Stage \>T2b                            1.60--4.38            0.0002                                
  low risk group                         ref.                                                        
  intermediate risk group                0.44--3.80            0.65                                  
  high risk group                        1.37--10.61           0.01                    1.86--5.21    \<0.0001
  Metastasis free survival                                                                           
  Characteristics                        Univariate analysis   Multivariate analysis                 
  HR (95% CI)                            *p* value             HR (95% CI)             *p* value     
  Age                                    0.96--1.14            0.32                                  
  Gleason score \<7                      ref.                                                        
  Gleason score = 7                                            0.96                                  
  Gleason score \>7                                            0.95                                  
  iPSA \<10                              ref.                                                        
  iPSA 10--20                            0.10--2.67            0.43                                  
  iPSA \>20                                                    0.96                                  
  Stage \<T2b                            ref.                                                        
  Stage = T2b                                                  0.97                                  
  Stage \>T2b                            0.80--16.26           0.10                                  
  low risk group                         ref.                                                        
  intermediate risk group                                      0.96                                  
  high risk group                                              0.95                    1.03--73.74   0.047
  -------------------------------------- --------------------- ----------------------- ------------- ----------

Abbreviation: ref.: reference

10.1371/journal.pone.0236026.t004

###### Results of post-HIFU prostate biopsy.
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  Biopsy methods             No. of patients   Residual cancer   HIFU-biopsy interval (mo), mean
  -------------------------- ----------------- ----------------- ---------------------------------
  Transurethral biopsy       32                4                 13.54
  Sonography-guided biopsy   27                10                15.31

10.1371/journal.pone.0236026.t005

###### Characteristics of patients receiving post-HIFU prostate biopsy.
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  Characteristics                     Residual cancer (N = 14)   Negative (N = 45)
  ----------------------------------- -------------------------- -------------------
  Age (yr), mean (range)              67.5 (54.0--82.9)          69.0 (57.8--85.1)
  Gleason score, N (%)                                           
   \<7                                2 (14.3%)                  14 (31.1%)
    = 7                               10 (71.4%)                 18 (40.0%)
   \>7                                2 (14.3%)                  13 (28.9%)
  iPSA, N (%)                                                    
   \<10                               8 (57.1%)                  24 (60.0%)
   10--20                             5 (35.7%)                  15 (33.3%)
   \>20                               1 (7.1%)                   6 (13.3%)
  Stage (%)                                                      
   \<T2b                              10 (71.4%)                 27 (60.0%)
   T2b                                0 (0.0%)                   5 (11.1%)
   \>T2b                              4 (28.6%)                  13 (28.9%)
  D'Amico risk group, N (%)                                      
   Low                                1 (7.1%)                   8 (17.8%)
   Intermediate                       7 (50.0%)                  13 (28.9%)
   High                               6 (42.9%)                  24 (53.3%)
  Biochemical recurrence, N (%)       8 (57.1%)                  19 (42.2%)
  Salvage treatment arranged, N (%)   14 (100%)                  24 (53.3%)

10.1371/journal.pone.0236026.t006

###### Relationships between post-HIFU PSA and post-HIFU prostate biopsy.
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  Sonography-guided biopsy            Positive of malignancy (N = 10)   Negative of malignancy (N = 17)   *p* value
  ----------------------------------- --------------------------------- --------------------------------- -----------
  iPSA, mean (ng/ml)                  12.5                              22.8                              0.29
  post-HIFU PSA nadir, mean (ng/ml)   0.3                               1.4                               0.15
  biochemical recurrence, N           7                                 13                                0.72

Functional outcomes {#sec006}
-------------------

Functional outcomes are summarised in [Table 7](#pone.0236026.t007){ref-type="table"}. With the same cohort, our previous study reported a 65.6% rate of *de novo* erectile dysfunction after primary HIFU. The IIEF-5 score was 22.10 ± 2.62 preoperatively and 9.36 ± 6.33 at 24 months after HIFU \[[@pone.0236026.ref005]\]. Three patients had urinary incontinence. Acute epididymitis developed in 10.9% of patients. Mean onset time of acute epididymitis was 22.6 days after operation (range: 8--71 days). Bladder neck contracture and urethral stricture, which require further surgical treatment under anaesthesia, were found in 20.3% of patients. One instance of rectourethral fistula was noted after salvage radiotherapy in our cohort. The rate of adverse events after salvage treatment was acceptable ([Table 8](#pone.0236026.t008){ref-type="table"}).

10.1371/journal.pone.0236026.t007

###### Adverse events after primary HIFU.
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  Adverse events                                  N = 128
  ----------------------------------------------- ---------
  Urinary incontinence                            2.3%
  Acute epididymitis                              10.9%
  Bladder neck contracture / Urethral stricture   20.3%
  De novo erectile dysfunction                    65.6%

10.1371/journal.pone.0236026.t008

###### De novo adverse events after salvage treatments.
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  Adverse events               CTCAE v5.0   Salvage HIFU (N = 13)   Salvage radiotherapy (N = 25)   *p* value
  ---------------------------- ------------ ----------------------- ------------------------------- -----------
  Urinary incontinence         Grade 1--2   0 (0.0%)                4 (16.0%)                       0.13
  Grade 3                      0 (0.0%)     0 (0.0%)                0.05                            
  Urinary tract obstruction    Grade 1--2   1 (7.7%)                4 (16.0%)                       0.48
  Grade 3                      2 (15.4%)    3 (12.0%)               0.77                            
  Gastrointestinal disorders   Grade 1--2   0 (0.0%)                5 (20.0%)                       0.09
  Grade 3                      0 (0.0%)     1 (4%)                  0.47                            

Discussion {#sec007}
==========

In Taiwan, the incidence of prostate cancer is increasing during the last decade. becoming a serious health problem. Radical prostatectomy and radiation therapy have been the standard treatments for localised prostate cancer. However, many patients, especially aged patients or patients with multiple comorbidity, may be concerned about adverse events after major surgery and radiation therapy. Minimally invasive treatment modality such as HIFU is a potential alternative option. Sufficient data concerning the long-term oncological outcomes of using HIFU as the treatment of localised prostate cancer remain lacking. Our previous study and another study reported median times to biochemical recurrence of 12.03 and 13.8 months, respectively \[[@pone.0236026.ref010]\]. Therefore, medium-term data collected after primary HIFU may be used as an indicator of the oncological outcomes of HIFU. Dickinson et al. reported an overall 5-year BRFS rate of 68% in a multicenter cohort where 16% of patients were in the high-risk group \[[@pone.0236026.ref011]\]. Durán-Rivera et al. also reported a comparable rate of 64.2% after 86.4 months of follow-up in a cohort where 3% were high-risk patients \[[@pone.0236026.ref012]\]. The proportion of high-risk group patients in our study, at 47%, was larger than those in previous studies, but our observed oncological outcomes are comparable to theirs. In low- and intermediate-risk patients, 5-year salvage treatment--free survival and biochemical recurrence--free survival rates were approximately 70% and 80%, respectively. The overall 5-year BRFS rate after primary HIFU was 64.8%. Median time to nadir PSA was only 2.52 months. Such early biochemical response is consistent with previous studies \[[@pone.0236026.ref013], [@pone.0236026.ref014]\].

There has been no series report on salvage treatment after primary HIFU. Our salvage treatment after primary HIFU included secondary HIFU and radiation therapy. More than 70% of patients who underwent radiation therapy, with or without ADT, were biochemical recurrence free, whereas only approximately half the patients who received secondary HIFU were biochemical recurrence free. In most patients with biochemical recurrence after secondary HIFU, radiation therapy can still be used to achieve BRFS. The overall BRFS rate after primary HIFU, with or without salvage treatment, was 90.6% in our series. Oncological outcomes after primary WG-HIFU are comparable with other treatment modalities for localised prostate cancer. Although the proportion of high-risk patients was disproportionately high in our series, our observed oncological outcomes are comparable to those of other treatment modalities and previous studies of HIFU.

We observed rates of 2.3% for urinary incontinence, 65.6% for *de novo* erectile dysfunction, 11.5% for acute epididymitis, and 20.3% for urethral stricture and bladder neck contracture. These adverse event rates are comparable with those of other studies \[[@pone.0236026.ref015]--[@pone.0236026.ref017]\]. As evident in [Table 3](#pone.0236026.t003){ref-type="table"}, the rate of urethral stricture and bladder neck contracture was significantly reduced to 10.5% after routine bougienage. Those who received prophylactic bilateral vasectomy tended to have a lower risk of acute epididymitis. No instance of rectourethral fistula was noted in the primary HIFU. However, one rectourethral fistula occurred after salvage radiotherapy.

According to the EORTC 22991 trial, of 28 patients who received 74 Gy intensity- modulated radiation therapy (IMRT) as primary treatment for localised prostate cancer, 46.4% of patients had grade 1 acute genitourinary toxicity, 25% had grade 2, and 10.7% had grade 3. In the same patient group, 39.3% of patients had grade 1 acute gastrointestinal toxicity and 7.1% had grade 2 \[[@pone.0236026.ref018]\]. By contrast, in this study, among patients who received salvage radiotherapy (at 66--70 Gy), only 12% had grade 1 acute genitourinary toxicity, and only 8% had grade 1 acute gastrointestinal toxicity. No toxicity grades \>1 were reported after salvage radiotherapy. The difference in the incidence of adverse events between patients who received primary and salvage radiotherapy may result from different radiotherapy dosages.

The major limitation of this study was its retrospective design. However, oncological outcomes after primary HIFU for localised prostate cancer were determined to be acceptable relative to radical prostatectomy and radiotherapy. HIFU is an alternative for the treatment of localised prostate cancer with minimal adverse events. Moreover, we identified disease relapse mainly by elevated PSA. However, MRI may provide a more sensitive test. MRI could detect imaging change of residual prostatic tissue where despite not elevating PSA. However, only x/y (%) who meet criteria of biochemical recurrence received post-HIFU MRI due to suspicion of disease relapse.

In general, our study demonstrated a feasible solution for the reduction of postoperative bladder neck contracture, urethral stricture, and acute epididymitis. Our observations of outcomes after salvage treatment with radiotherapy or secondary HIFU were also reported in this paper. In total, 90.6% of patients with localised prostate cancer in our institute could achieve BRFS (at a median of 53.7 months) following primary HIFU or subsequent salvage treatment with secondary HIFU or radiotherapy.

Conclusions {#sec008}
===========

WG-HIFU is an effective treatment option for localised prostate cancer, especially in D'Amico low- and intermediate-risk diseases. Although some patients experienced PSA biochemical recurrence, the success rate of salvage treatment was still acceptable. Salvage radiation therapy may play an important role in biochemical recurrence after primary HIFU. In addition, the complication rate after primary HIFU was lower than that for other treatment modalities. Long-term follow-up of 10 to 15 years is still required for oncological control.

This manuscript was edited by Wallace Academic Editing. We appreciate the Biostatistics Center, Kaohsiung Chang Gung Memorial Hospital.
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Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors provided medium term oncological outcomes of a single institution cohort of 128 men receiving whole gland HIFU for clinically localized prostate cancer.

Major comments:

1\. I would specify that the study describes whole gland HIFU. Modify and introduce an abbreviation for whole gland HIFU throughout the manuscript.

2\. Abstract does not read well. For example, the first proposition does not fit neither with the background nor with the objective of the study. No information are given regarding the efficacy of salvage treatments. Please address this point.

3\. Did all patients received a post whole gland HIFU biopsy? Please clarify

4\. A table (or a Kaplan meier in case the follow up biopsy protocol was not standardized) showing the results of the follow up biopsy would be useful.

5\. Which were the criteria, if there were any, to choose the salvage treatment strategy? Please describe.

6\. If the authors are keen on reporting data regarding the efficacy of salvage treatments is necessary to report also the outcomes of the population receiving any salvage treatment (as subgroup analysis and figures as supplementary)

7\. Since all men received a pre mpMRI, isit possible to add any information regarding the presence of visible lesions, PI-RADS score etc?

8\. Regarding the functional outcomes, which represent secondary outcomes according to the study's methods, only data regarding the study population should be reported. All information regarding not included cohort should be removed since not relevant.

9\. Unless preop IIEF is available, any data regarding post op IIEF should be removed since not reliable.

10\. Adverse events should be put in one single table and, if possible, compared for each procedure (provide a p value if possible)

11\. The first sentence of the discussion part is out of context and biased. Please change the beginning of this paragraph

Reviewer \#2: 1. The major concern on this works is that it is supported the manuscript a small number of patients and a very short period in this manuscript.

2\. Abstract-too much space is spent on descriptive data and not enough space on the main result of the study.

3\. The author mentions in materials and methods that 405 patients with prostate cancer have been treated with HIFU from December 2009 to February 2015. From December 2009 to February 2015, 161 patients who were newly diagnosed with prostate cancer were enrolled. In total, 128 patients were included (Figure 1). It is not cleared why the author selected only 128 patients in this study and Fig.1 is confusing to understand.

4\. A small group of population main concern.

Out of 161, only 128 enrolled patients were included. Not clear about the missing population in this study. Is it due to side effects? 20 patients were

excluded because of their follow-up durations were less than 30 months (not clear about missing data during that time and follow up).

Excluded 28 of 128 patients who were undergoing ADT during follow-up (Figure 1)??

Two patients were lost to follow-up (not clear)??

A very small group of studies to compare: Of the remaining 98 patients, 60 (61.2%) patients had no biochemical recurrence and thus did not require any salvage treatment, and 38 (38.8%), patients received salvage treatment due to biochemical recurrence.

Conclusion: Large group of the population required for efficacy and safety of the treatment. Clarification required for lost to follow up.

5\. Prostate-specific antigen: It is very important to know the PSA levels for prostate cancer patients. So, all patients had PSA levels measured three to six months for the first few years to check how well the HIFU and salvage treatment has worked. So, I would recommend a Table including prostate-specific antigen and histology after high intensity focused ultrasound.

6\. MRI analysis: MRI may provide a more sensitive test than PSA, as it can detect disease not elevating PSA but causing a change in the MRI features of residual prostatic tissue. Second, when the disease is detected on MRI, imaging also provides the location of the disease and therefore has the added advantage of being able to guide biopsy and salvage therapy by MRI analysis and the image need to include in the picture.

7\. The author showed that patients with the high-risk group had shorter BCR and salvage treatment-free survival than prostate cancer patients with a low and intermediate group (P\<0.0001) (Figure 2 and Figure 3). To determine whether the high-risk group has independent prognostic value, univariate and multivariate analysis needs to be performed.

8\. I would recommend providing a table of Kaplan-Meier analysis of metastasis-free survival in Figure 4. What is the probability? How do certain personal, behavioral or clinical characteristics chances of survival?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Click here for additional data file.
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Author response to Decision Letter 0

9 Apr 2020

Dear editor and reviewers:

Thanks for the time and effort you spent assessing the previous version of the manuscript.

For the previous table 3 (table 7 in the revised manuscript), the IIEF questionnaire was not done for most patients in that time frame, so we typed "N/A" for de novo erectile dysfunction. The column was deleted for irrelevance to the cohort of this article as reviewer's suggestion. Other responses to the comments are as below and all of your suggestions are incorporated into revised manuscript.

Reviewer \#1: The authors provided medium term oncological outcomes of a single institution cohort of 128 men receiving whole gland HIFU for clinically localized prostate cancer.

1\. I would specify that the study describes whole gland HIFU. Modify and introduce an abbreviation for whole gland HIFU throughout the manuscript.

\--\> Thanks for this suggestion. Whole-gland HIFU may be abbreviated as WG-HIFU. It was revised in the manuscript.

2\. Abstract does not read well. For example, the first proposition does not fit neither with the background nor with the objective of the study. No information are given regarding the efficacy of salvage treatments. Please address this point.

\--\> The abstract was revised according to your suggestion. Thanks!

3\. Did all patients received a post whole gland HIFU biopsy? Please clarify

\--\> Post-HIFU prostate biopsy was not routinely arranged. It might be arranged because of biochemical recurrence. It might also be arranged for patients not meeting criteria of biochemical recurrence but worry about continuous elevation of PSA. We will add this paragraph to manuscript (p5, line 122-125).

4\. A table (or a Kaplan meier in case the follow up biopsy protocol was not standardized) showing the results of the follow up biopsy would be useful.

\--\> Tables 4 and 5 showing the results of post-HIFU biopsy was added to the paragraph. Thanks for the suggestion.

5\. Which were the criteria, if there were any, to choose the salvage treatment strategy? Please describe.

\--\> Of patients with residual tumor noted, secondary HIFU will be arranged. Of patients with local lymph node metastasis suspected, salvage radiotherapy will be suggested. Salvage radiotherapy with half to one year of ADT is the standard strategy. We will add this paragraph to manuscript (p6, line 130-134).

6\. If the authors are keen on reporting data regarding the efficacy of salvage treatments is necessary to report also the outcomes of the population receiving any salvage treatment (as subgroup analysis and figures as supplementary)

\--\> Thanks for the suggestion. Experience of post-HIFU salvage treatment is relatively scarce. Therefore, we think we could try to share our experience after years of HIFU use. However, only 38 patients received salvage HIFU or salvage radiation therapy in this study. Their outcome was shown in figure 1. We also added some explanation about salvage treatment.

7\. Since all men received a pre mpMRI, is it possible to add any information regarding the presence of visible lesions, PI-RADS score etc?

\--\> Thanks for this suggestion. Actually, of all 128 patients enrolled, only 12 patients received pre-HIFU mpMRI and the rest 116 patients received pre-HIFU pelvic CT. Since the number of mpMRI is small in this series, we are afraid that we cannot provide any new information about this issue.

8\. Regarding the functional outcomes, which represent secondary outcomes according to the study's methods, only data regarding the study population should be reported. All information regarding not included cohort should be removed since not relevant.

\--\> The irrelevant sentences and table were removed (p15). Thanks!

9\. Unless preop IIEF is available, any data regarding post op IIEF should be removed since not reliable.

\--\> Preoperative IIEF was added to the paragraph (p15, line 232-233). Thanks for the suggestion.

10\. Adverse events should be put in one single table and, if possible, compared for each procedure (provide a p value if possible)

\--\> The table regarding adverse events was revised and shown in table 8.

11\. The first sentence of the discussion part is out of context and biased. Please change the beginning of this paragraph

\--\> Thanks for the reminder. This paragragh was revised (p16, line 261-266).

 

Reviewer \#2:

1\. The major concern on this works is that it is supported the manuscript a small number of patients and a very short period in this manuscript.

\--\> Thanks for the comment. This is a median 5-year follow-up study. We share our HIFU experience because there are only a few papers of HIFU treatment of prostate cancer.

2\. Abstract-too much space is spent on descriptive data and not enough space on the main result of the study.

\--\> The abstract was revised. Thanks for the suggestion!

3\. The author mentions in materials and methods that 405 patients with prostate cancer have been treated with HIFU from December 2009 to February 2015. From December 2009 to February 2015, 161 patients who were newly diagnosed with prostate cancer were enrolled. In total, 128 patients were included (Figure 1). It is not cleared why the author selected only 128 patients in this study and Fig.1 is confusing to understand.

\--\> We are sorry about the misunderstanding. In our institution, we performed the first HIFU in December 2009. From December 2009 to December 2019, when we submitted the original manuscript, there are 405 patients treated with HIFU. With the concern of adequate follow-up period, we only enrolled 161 patients treated with HIFU during December 2009 to February 2015.

4\. A small group of population main concern.

Out of 161, only 128 enrolled patients were included. Not clear about the missing population in this study. Is it due to side effects? 20 patients were

excluded because of their follow-up durations were less than 30 months (not clear about missing data during that time and follow up).

Excluded 28 of 128 patients who were undergoing ADT during follow-up (Figure 1)??

Two patients were lost to follow-up (not clear)??

A very small group of studies to compare: Of the remaining 98 patients, 60 (61.2%) patients had no biochemical recurrence and thus did not require any salvage treatment, and 38 (38.8%), patients received salvage treatment due to biochemical recurrence.

Conclusion: Large group of the population required for efficacy and safety of the treatment. Clarification required for lost to follow up.

\--\> Of the 128 patients, 28 patients received ADT after primary HIFU as a role of salvage treatment because of biochemical recurrence or slight elevation of PSA without biochemical recurrence. Ten of the 28 patients stopped ADT months later and no more PSA elevation occurred. Eleven of the 28 patients still receive ADT currently and PSA level remain stable. Seven of the 28 patients still receive ADT currently, but gradual elevation of PSA is noted. However, they refuse or hesitate about further salvage treatment such as radiation therapy or secondary HIFU.

Since 41 of 45 (91%) suffered from biochemical recurrence within 30 months during follow-up, therefore, we excluded patients whose follow-up duration is less than 30 months to avoid missing biochemical recurrence.

5\. Prostate-specific antigen: It is very important to know the PSA levels for prostate cancer patients. So, all patients had PSA levels measured three to six months for the first few years to check how well the HIFU and salvage treatment has worked. So, I would recommend a Table including prostate-specific antigen and histology after high intensity focused ultrasound.

\--\> Thanks for the suggestion. The relationships between post-HIFU PSA and post-HIFU prostate biopsy was shown in table 6.

6\. MRI analysis: MRI may provide a more sensitive test than PSA, as it can detect disease not elevating PSA but causing a change in the MRI features of residual prostatic tissue. Second, when the disease is detected on MRI, imaging also provides the location of the disease and therefore has the added advantage of being able to guide biopsy and salvage therapy by MRI analysis and the image need to include in the picture.

\--\> Really thanks for your suggestion. We have described this method in the discussion in the revised manuscript (p19, line 330-334).

7\. The author showed that patients with the high-risk group had shorter BCR and salvage treatment-free survival than prostate cancer patients with a low and intermediate group (P\<0.0001) (Figure 2 and Figure 3). To determine whether the high-risk group has independent prognostic value, univariate and multivariate analysis needs to be performed.

\--\> Univariate and multivariate analysis were performed and showed in table 3.

8\. I would recommend providing a table of Kaplan-Meier analysis of metastasis-free survival in Figure 4. What is the probability? How do certain personal, behavioral or clinical characteristics chances of survival?

\--\> Associated univariate and multivariate analysis was performed and showed in table 3.
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Submitted filename: Response to Reviewers.docx
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Click here for additional data file.
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Hsieh

Jason Chia-Hsun

Academic Editor

© 2020 Jason Chia-Hsun Hsieh

2020

Jason Chia-Hsun Hsieh

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

25 May 2020

PONE-D-20-00019R1

Cohort study of high-intensity focused ultrasound in the treatment of localised prostate cancer treatment: medium-term results from a single centre

PLOS ONE

Dear Dr. Chiang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Please kindly address the minor issues from the reviewer. 

==============================

Please submit your revised manuscript by Jul 09 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Jason Chia-Hsun Hsieh, M.D. Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Please kindly address the minor issues from the reviewer.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors did a pretty good job addressing all the comments.

Further minor comments:

1\) Table 3: provide HRs for both univariate and multivariate in a clearer way so that the reader can understand the confounders. logHRs not required

2\) Please clarify what endoscopic biopsy means

3\) Table 5: provide both raw numbers and percentages for each figures

4\) positive/negative of malignancies sounds pretty bad. Rewrite it.

5\) Please be consistent with the use of the short WG-HIFU

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236026.r004

Author response to Decision Letter 1

23 Jun 2020

Reviewer \#1:

Further minor comments:

1\) Table 3: provide HRs for both univariate and multivariate in a clearer way so that the reader can understand the confounders. logHRs not required

\--\> Table 3 was revised according to suggestion of the Biostatistics Center of our institution.

2\) Please clarify what endoscopic biopsy means

\--\> Endoscopic biopsy means transurethral biopsy by monopolar loop.

3\) Table 5: provide both raw numbers and percentages for each figures

\--\> In table 5, percentage was added for each figures.

4\) positive/negative of malignancies sounds pretty bad. Rewrite it.

\--\> The terms were revised.

5\) Please be consistent with the use of the short WG-HIFU

\--\> Whole manuscript was examined and the WG-HIFU is used consistently.
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© 2020 Jason Chia-Hsun Hsieh
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Jason Chia-Hsun Hsieh

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

29 Jun 2020

Cohort study of high-intensity focused ultrasound in the treatment of localised prostate cancer treatment: medium-term results from a single centre

PONE-D-20-00019R2

Dear Dr. Chiang,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Jason Chia-Hsun Hsieh, M.D. Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

All the questions were answered adequately.

Reviewers\' comments:

10.1371/journal.pone.0236026.r006
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Jason Chia-Hsun Hsieh

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

8 Jul 2020

PONE-D-20-00019R2

Cohort study of high-intensity focused ultrasound in the treatment of localised prostate cancer treatment: medium-term results from a single centre

Dear Dr. Chiang:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jason Chia-Hsun Hsieh

Academic Editor

PLOS ONE
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